Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3693523013 | Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3693525018 | Erythromycin 20 mg/g and isotretinoin 500 microgram/g cutaneous gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3548581000005114 | isotretinoin + erythromycin 0,05 %/2 % gel | da | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Is a | erythromycin til topikal anvendelse | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing isotretinoin (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Erythromycin (substance) | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Hudmiddel | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Isotretinoin (substance) | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing erythromycin and isotretinoin (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Baktericid | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | kutan OG/ELLER transdermal doseringsform | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | A semi-solid dose form consisting of a hydrophilic gel. | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Cutaneous gel | true | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Is a | isotretinoin til topikal anvendelse | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 500 | false | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 20 | false | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mg | false | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mcg | false | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Isotretinoin (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the denominator unit for the concentration strength of a product. | g | true | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Erythromycin (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the denominator unit for the concentration strength of a product. | g | true | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Isotretinoin (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Erythromycin (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Erythromycin and isotretinoin only product in cutaneous dose form | true | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | Plays role | Antibacterial therapeutic role (role) | false | Inferred relationship | Some | ||
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Erythromycin (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Isotretinoin (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Erythromycin (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Isotretinoin (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) | This attribute specifies the numerator unit for the concentration strength of a product. | mcg | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR